Studies of the first three months report an average loss of 7.3% to 8.8% of body weight. In a real-world study of 115 adults without diabetes, twelve weeks of tirzepatide took off 8.2 kg on average, or 7.3% [1]. Tirzepatide is the drug in Zepbound. Those patients never went above 5 mg. In the SURMOUNT-1 trial, 82% of participants who took their doses had lost at least 5% by week 12 [2].
Three months is an early checkpoint, not a result. The bigger numbers quoted for Zepbound are 72-week figures at higher doses. How early a response can be read at all is covered in how long a GLP-1 takes to work. What predicts the final number is in how much weight you will lose on a GLP-1. This page covers the first twelve weeks on tirzepatide only.
What three months of real-world use produced
Three published cohorts report a twelve-week average. A figure from one is usable only with its dose and its population attached.
The first is a prospective study across several centers [1]. It enrolled 115 adults with obesity and no diabetes. Everyone took 2.5 mg weekly for 4 weeks, then 5 mg to week 12. Mean weight fell by 8.2 kg, or 7.3%. Fewer than half, 46.1%, had reached 5% by then. Nausea was the most common side effect, at 7.8%.
The second comes from the same research group and measured body composition in 51 adults [3]. Weight fell by 8.75 kg over 12 weeks, or 8.18%. About 78% of the weight lost was fat mass. The abstracts do not say whether the two groups overlap. So the two are read side by side, never added together. How the fat-to-lean split compares over a full course is in whether a GLP-1 causes muscle loss.
The third is a telehealth weight program [4]. Its mean change at 12 weeks was 20.12 pounds, or 8.80%. That figure carries two conditions. It counts only the 1,166 patients who completed at least 52 weeks. It also pools branded and compounded tirzepatide.
What the trial shows at week 12
SURMOUNT-1 randomized 2,539 adults without diabetes to tirzepatide or placebo for 72 weeks [5]. The first 20 of those weeks were a dose-escalation period. Week 12 falls inside it, so nobody in the trial was yet on a final dose.
A post hoc analysis sorted 1,545 tirzepatide-treated participants at week 12 [2]. It included only those who had taken at least 75% of their doses. Of these, 1,267, or 82%, had lost at least 5%. The other 278, or 18%, had not.
The slower group did not stay slow. By week 24, 70% of them had passed 5%. By week 72, 90% had. Their mean time to reach 5% was 24.8 weeks. Higher doses went with higher shares reaching each weight threshold at weeks 24 and 72.
The abstract gives shares, not a mean week-12 change. This page therefore quotes no trial average for month 3. Any figure presented as the trial’s three-month mean should name where it came from.
Why month 3 is a low-dose month
The label sets the pace. The starting dose is 2.5 mg weekly for 4 weeks [6]. It then rises to 5 mg. After that, each step is 2.5 mg, taken for at least 4 weeks first. The 2.5 mg dose is for starting only and is not approved for maintenance.
Followed at the fastest pace allowed, that is 2.5 mg in weeks 1 to 4 and 5 mg in weeks 5 to 8. Weeks 9 to 12 are on 7.5 mg. The 10 mg dose cannot start before week 13. The 15 mg dose cannot start before week 21.
The trial headlines are 72-week results at 5, 10 and 15 mg [5]. Mean weight change was −15.0%, −19.5% and −20.9% respectively, against −3.1% on placebo. None of those describes month 3. Outside trials, escalation is often slower still: most tirzepatide buyers stayed under 10 mg through six fills.
That has a price consequence. A seller’s first three months are billed at the low rungs of the ladder. A quote at 15 mg describes a month most buyers have not reached. The running total is in what six months comes to.
Where month 3 sits on the full curve
Weight loss on tirzepatide is not finished at three months. A second post hoc analysis defined a plateau as less than 5% change over a 12-week window [7]. The median time to reach it in SURMOUNT-1 ran from 24.3 weeks in the overweight group to 36.1 weeks in the two highest obesity classes. Most participants had plateaued by week 72.
Higher doses, younger age and female sex went with a later plateau. So a three-month figure is taken early in the curve, on a low dose, before most people have leveled off.
How tirzepatide compares at month 3
One large American cohort compared tirzepatide with semaglutide in routine care [8]. Both were the formulations labeled for type 2 diabetes. At 3 months, weight change was 2.4 percentage points larger on tirzepatide. The gap widened to 4.3 points at 6 months.
The abstract reports those as differences, not as each drug’s own result. It also records that discontinuation ended follow-up for 55.9% of the tirzepatide group. A smaller three-month comparison, run at mismatched doses, is in tirzepatide against semaglutide at two doses nobody matched. Whether the extra loss justifies the price is priced in whether tirzepatide is worth the extra cost.
What a slow first three months means
Less than 5% at week 12 is common. In the trial it applied to nearly one participant in five. In the 5 mg real-world cohort it applied to more than half.
On the trial evidence, it predicts a later response rather than a failed one. Nine in ten of the slower trial group passed 5% by week 72. The decision to continue belongs with the prescriber, and it rests on the dose reached as well as the scale. Why some people barely respond at all is covered in why some people do not lose weight on a GLP-1. How many stay on long enough to find out is in how long people stay on a GLP-1.